Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: A preliminary study

International Journal of Clinical Oncology

Volumn 8, Issue 1, 2003, Pages 45-48

  Nishio, Shin ^a   Ota, Shunichiro ^a   Sugiyama, Toru ^a   Matsuo, Go ^a   Kawagoe, Hidehiro ^a   Kumagai, Seisuke ^a   Ushijima, Kimio ^a   Nishida, Takashi ^a   Kamura, Toshiharu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Paclitaxel; Recurrent endometrial cancer; Weekly 1 h infusion

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIUM CARCINOMA; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MYALGIA; NAIL COLOR DEFECT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ONYCHORREXIS; OUTPATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE PROGRESSION; DRUG EVALUATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROTOXICITY SYNDROMES; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PLEURODYNIA, EPIDEMIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 0037295408     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470300006     Document Type: Article

References (20)

1. Park RC, Griby PW, Muss HB (1992) Corpus: epithelial tumors. In: Hokins WJ, Perez CA, Young RC, et al. (eds) Principles and practice of gynecologic oncology. Saunders, Philadephia, pp 663-693
2. Muss HB (1994) Chemotherapy of metastatic endometrial cancer. Semin Oncol 21:107-113
3. Moore TD, Phillips PH, Nerenstone SR, et al. (1991) Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 9:1071-1088
4. Turbow MM, Ballon SC, Sikic BI, et al. (1985) Cisplatin, doxorubicin, and cyclophos-phamide chemotherapy for advanced endometrial carcinoma. Cancer Treat Rep 69:465-469
5. Hancock KC, Freedman RS, Edwards CL, et al. (1986) Use of cisplatin, doxorubicin and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 70:789-791
6. Ball HG, Blessing JA, Lentz SS, et al. (1996) A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a gynecologic oncology study. Gynecol Oncol 62:278-281
7. Woo HL, Swenerton KD, Hoskins PJ (1996) Taxol is active in platinum-resistant endometrial adenocarcinoma. Am J Clin Oncol 19:290-291
8. Lissoni A, Zanetta G, Losa G, et al. (1996) Phase II study of paclitaxel as salvage treatment in advanced endomerial cancer. Ann Oncol 7:861-863
9. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus short low dose and long versus short infusion. J Clin Oncol 19:2654-2666
10. Blat O, Kudelka P, Tunca JC, et al. (1996) Prolonged stabilizaion of progressive platinum-refractory ovarian cancer with paclitaxel: brief report. Eur J Gynecol Oncol 17:264-266
11. Schiller JH, Storer B, Tutsh K, et al. (1994) Phase I trial of 3-h infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 12:241-248
12. Greco FA, Hainsworth JD (1994) Paclitaxel: phase I/II trial comparing 1 h infusion in schedules. Semin Oncol 21:3-8
13. Tsavaris N, Kosmas AP, Giannikos L, et al. (1997) A feasibility study of 1 h paclitaxel infusion in patients with solid tumors. Cancer Chemother Pharmacol 40:353-357
14. Abu-Rustum N, Aghajanian C, Barakat RR, et al. (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:S15-62-S15-67
15. Loffler TM, Freund W, Lipke J, et al. (1996) Schedule and dose intensified paclitaxel as weekly 1 h infusion in pretreated solid tumors:results of a phase I/II trial. Semin Oncol 23:32-34
16. Fennelly D, Aghajanian C, Shapiro F, et al. (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192
17. Klaassen U, Wilke H, Strumberg D, et al. (1996) Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-549
18. Andersson H, Boman K, Ridderheim M, et al. (2000) An updated analysis of a randomized study of single agent paclitaxel given weekly vs every 3 weeks to patients with ovarian cancer treated with prior platinum therapy (abstract). Proc Am Soc Clin Oncol 19:380
19. Seidman AD, Hudis CA, Albanel J, et al. (1998) Dose-dense therapy with weekly 1-h paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
20. Ota S, Sugiyama T, Komai K, et al. (2001) Weekly 1 h paclitaxel infusion in patients with recurrent gynecological tumos: a pilot study. Jpn J Clin Oncol 31:395-398